Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer

Philip C Mack¹, Jorge E Gomez¹, Ananda M Rodilla¹, Juan Manuel Carreño², Chih-Yuan Hsu³, Christian Rolfo¹, Noy Meshulami¹, Amy Moore⁴, Rachel I Brody⁵, Jennifer C King⁶, Jacquelyn Treatman¹, Sooyun Lee¹, Ariel Raskin², Komal Srivastava², Charles R Gleason², Diego de Miguel-Perez¹; PARIS/PSP study group⁷; Johnstone Tcheou², Dominika Bielak², Rashmi Acharya⁶, David E Gerber⁸, Nicholas Rohs¹, Claudia I Henschke⁹, David F Yankelevitz⁹, Viviana Simon¹⁰, John D Minna⁸, Paul A Bunn Jr¹¹, Adolfo García-Sastre¹², Florian Krammer¹³, Yu Shyr³, Fred R Hirsch¹⁴

Collaborators, Affiliations

Collaborators

PARIS/PSP study group:
D Andre, H Alshammary, H van Bakel, M C Bermúdez-González, G Cai, C Cognigni, D Floda, A Firpo, G Kleiner, N Lyttle, W Mendez, L C F Mulder, A Oostenink, A Rooker, A Salimbangon, M Saksena, L Sominsky, E M Sordillo

Affiliations

¹ Center for Thoracic Oncology, Tisch Cancer Institute and Icahn School of Medicine at Mount Sinai, New York, NY, USA.
² Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center for Vaccine Research and Pandemic Preparedness (C-VARPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA.
³ Department of Biostatistics, Vanderbilt University, Nashville, TN, USA.
⁴ LUNGevity Foundation, Bethesda, MD, USA.
⁵ Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
⁶ GO2 Foundation for Lung Cancer, Washington, DC, USA.
⁷ Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
⁸ Hamon Center for Therapeutic Oncology Research, Departments of Internal Medicine and Pharmacology UT Southwestern Medical Center, Dallas, TX, USA.
⁹ Diagnostic, Molecular and Interventional Radiology, Mount Sinai Health System, New York, NY, USA.
¹⁰ Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center for Vaccine Research and Pandemic Preparedness (C-VARPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA.
¹¹ Department of Internal Medicine, University of Colorado Cancer Center, Denver, CO, USA.
¹² Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
¹³ Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center for Vaccine Research and Pandemic Preparedness (C-VARPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA.
¹⁴ Center for Thoracic Oncology, Tisch Cancer Institute and Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: fred.hirsch@mssm.edu.

PMID: 35504289
PMCID: PMC9020481
DOI: 10.1016/j.ccell.2022.04.012

Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer

Philip C Mack et al. Cancer Cell. 2022.

. 2022 Jun 13;40(6):575-577.

doi: 10.1016/j.ccell.2022.04.012. Epub 2022 Apr 20.

Authors

Collaborators

PARIS/PSP study group:
D Andre, H Alshammary, H van Bakel, M C Bermúdez-González, G Cai, C Cognigni, D Floda, A Firpo, G Kleiner, N Lyttle, W Mendez, L C F Mulder, A Oostenink, A Rooker, A Salimbangon, M Saksena, L Sominsky, E M Sordillo

Affiliations

¹ Center for Thoracic Oncology, Tisch Cancer Institute and Icahn School of Medicine at Mount Sinai, New York, NY, USA.
² Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center for Vaccine Research and Pandemic Preparedness (C-VARPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA.
³ Department of Biostatistics, Vanderbilt University, Nashville, TN, USA.
⁴ LUNGevity Foundation, Bethesda, MD, USA.
⁵ Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
⁶ GO2 Foundation for Lung Cancer, Washington, DC, USA.
⁷ Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
⁸ Hamon Center for Therapeutic Oncology Research, Departments of Internal Medicine and Pharmacology UT Southwestern Medical Center, Dallas, TX, USA.
⁹ Diagnostic, Molecular and Interventional Radiology, Mount Sinai Health System, New York, NY, USA.
¹⁰ Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center for Vaccine Research and Pandemic Preparedness (C-VARPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA.
¹¹ Department of Internal Medicine, University of Colorado Cancer Center, Denver, CO, USA.
¹² Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
¹³ Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center for Vaccine Research and Pandemic Preparedness (C-VARPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA.
¹⁴ Center for Thoracic Oncology, Tisch Cancer Institute and Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: fred.hirsch@mssm.edu.

PMID: 35504289
PMCID: PMC9020481
DOI: 10.1016/j.ccell.2022.04.012

No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines, which list F.K. as co-inventor. V.S. is also listed on the serological assay patent application as co-inventor, and A.G.-S. is listed on the NDV-based SARS-CoV-2 vaccine as co-inventor. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. F.K. has consulted for Merck and Pfizer (before 2020) and is currently consulting for Pfizer, 3(rd) Rock Ventures, Seqirus, and Avimex. The Krammer laboratory is also collaborating with Pfizer on animal models of SARS-CoV-2. The Adolfo García-Sastre laboratory has received research support from Pfizer, Senhwa Biosciences, Kenall Manufacturing, Avimex, Johnson & Johnson, Dynavax, 7Hills Pharma, Pharmamar, ImmunityBio, Accurius, Nanocomposix, Hexamer, N-fold LLC, Model Medicines, Atea Pharma, and Merck, outside of the reported work. A.G.-S. has consulting agreements for the following companies involving cash and/or stock: Vivaldi Biosciences, Contrafect, 7Hills Pharma, Avimex, Vaxalto, Pagoda, Accurius, Esperovax, Farmak, Applied Biological Laboratories, Pharmamar, and Pfizer, outside of the reported work. J.D.M. acknowledges royalties from the NIH and UT Southwestern Medical Center for distribution of human cell lines. P.C.M. acknowledges honoraria from Amgen and Guardant Health. F.R.H. acknowledges scientific advisory board compensation from AstraZeneca/Daiichi, Genentech, Sanofi/Regeneron, Merck, Bristol-Myers Squibb, Novartis, Amgen, OncoCyte, Nectin Therapeutics, and Novocure. Institutional Research grants (University of Colorado): Amgen, Biodesix, Rain Therapeutics JCK: Advisory Boards: Boehringer Ingelheim, Bristol Myers Squibb, Invitae, Guardant. Institutional Research funding: Bristol Myers Squibb, Genentech, Novartis. C.R.: EMD Serono, AstraZeneca, Roche, Pfizer, Bristol Myer Squibb, Esai, BluePrint, CORE2, Sanofi-Regeneron, Mirati. J.E.G.: Advisory board for Bristol-Myer Squibb.

References

1. Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B., et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 2021;384:403–416. doi: 10.1056/nejmoa2035389. - DOI - PMC - PubMed
1. Chavez-Macgregor M., Lei X., Zhao H., Scheet P., Giordano S.H. Evaluation of COVID-19 mortality and Adverse Outcomes in US patients with or without cancer. JAMA Oncol. 2021;8:69–78. doi: 10.1001/jamaoncol.2021.5148. - DOI - PMC - PubMed
1. Krammer F., Srivastava K., Alshammary H., Amoako A.A., Awawda M.H., Beach K.F., Bermudez-Gonzalez M.C., Bielak D.A., Carreno J.M., Chernet R.L., et al. Antibody responses in Seropositive Persons after a Single dose of SARS-CoV-2 mRNA vaccine. N. Engl. J. Med. 2021;384:1372–1374. doi: 10.1056/nejmc2101667. - DOI - PMC - PubMed
1. Kuderer N.M., Choueiri T.K., Shah D.P., Shyr Y., Rubinstein S.M., Rivera D.R., Shete S., Hsu C.Y., Desai A., de Lima Lopes G., Jr., et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395:1907–1918. doi: 10.1016/S0140-6736(20)31187-9. - DOI - PMC - PubMed
1. Lievre A., Turpin A., Ray-Coquard I., Le Malicot K., Thariat J., Ahle G., Neuzillet C., Paoletti X., Bouche O., Aldabbagh K., et al. Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: a French nationwide cohort study (GCO-002 CACOVID-19) Eur. J. Cancer. 2020;141:62–81. doi: 10.1016/j.ejca.2020.09.035. - DOI - PMC - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer

Collaborators

Affiliations

Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer

Authors

Collaborators

Affiliations

Conflict of interest statement

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical